RBC Capital Reiterates Outperform on OptimizeRx, Maintains $17 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Sean Dodge reiterated an Outperform rating on OptimizeRx (NASDAQ:OPRX) and maintained a $17 price target.
April 01, 2024 | 1:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital maintains an Outperform rating on OptimizeRx with a $17 price target.
The reiteration of an Outperform rating and maintenance of a $17 price target by a reputable analyst like Sean Dodge from RBC Capital could instill confidence among investors and potentially lead to a positive short-term impact on OptimizeRx's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90